PRME241220C5000
- 0.05
- 0.000.00%
Prime Medicine Newsroom
Express News | Prime Medicine Inc Files for Resale of up to 11 Mln Common Shares by the Selling Stockholder - SEC Filing
JMP Securities Initiates Prime Medicine at Market Outperform With $10 Price Target
JMP Securities Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $10
Prime Medicine, Inc.: Innovative Gene Editing Platform With Significant Market Potential
Express News | Guggenheim Reiterates Buy on Prime Medicine, Maintains $18 Price Target
Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating, Maintains Target Price $5
Prime Medicine, Inc. (PRME) Gets a Hold From Morgan Stanley
A Quick Look at Today's Ratings for Prime Medicine(PRME.US), With a Forecast Between $7 to $14
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Prime Medicine Reports Q3 2024 Financial Progress
Prime Medicine Is Maintained at Buy by Chardan Capital
Prime Medicine, Inc.: Strategic Initiatives and Promising Developments Drive Buy Rating
Stifel Nicolaus Sticks to Its Hold Rating for Prime Medicine, Inc. (PRME)
Prime Medicine Analyst Ratings
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Express News | Prime Medicine Inc : Chardan Capital Markets Cuts Target Price to $15 From $17
TD Cowen Maintains Prime Medicine(PRME.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Nuvalent (NUVL)
Prime Medicine, Inc. (PRME) Receives a Buy From TD Cowen